Blue Chip Marketing Worldwide Accelerates Patient Enrollment for Orexigen Therapeutics Contrave® Light Study

  Blue Chip Marketing Worldwide Accelerates Patient Enrollment for Orexigen
  Therapeutics Contrave® Light Study

Blue Chip Patient Recruitment concludes study participant screenings 14 months
                              ahead of forecast

Business Wire

NORTHBROOK, Ill. -- December 21, 2012

Blue Chip Patient Recruitment (BCPR), a division of Blue Chip Marketing
Worldwide, a full-service integrated marketing agency, has successfully
partnered with Orexigen® Therapeutics (Nasdaq: OREX) to accelerate patient
enrollment of The Light Study, Orexigen’s cardiovascular outcomes trial
evaluating Contrave® (naltrexone sustained release (SR)/bupropion SR).
Approximately 9,000 patients will be randomized in the study within the next
few weeks, nearly 14 months ahead of original forecasts. Contrave is an
investigational medication being evaluated for the treatment of obesity.

The Light Study (www.lightstudy.com) is a randomized, double-blind,
placebo-controlled cardiovascular outcomes trial evaluating the occurrence of
major adverse cardiovascular events (MACE) in patients participating in the
study. The study, which began enrolling study participants in June 2012, was
originally projected to achieve its enrollment goal within 18-20 months of the
study launch.

According to the Center for Information & Study on Clinical Research
Participation, delays in patient recruitment for clinical trials account for
an average of 4.6 months lost per trial. Each day a drug is delayed from
reaching the market could cost sponsors up to $8 million in missed revenue.
Six percent of clinical trials are completed on time, and 72% of trials run
over schedule by more than one month.Currently about six cents of each health
dollar spent in the United States is spent on medical health and research.

Orexigen formed a strategic partnership with BCPR to consult and help with
clinical trial enrollment execution. BCPR conducted extensive market research
that led to the development of The Light Study brand and an integrated
communications platform. BCPR also deployed a team of Clinical Enrollment
Specialists, a first of its kind, field-based team of former study
coordinators whose sole responsibility was to serve as a positive, supportive
enrollment resource for study sites.These Clinical Enrollment Specialists
conducted site visits and regular telephone consultations to enhance
in-practice recruitment efforts and facilitate ad leads. In addition, BCPR
helped enhance the site selection process by identifying geographic
considerations that helped improve the effectiveness of the advertising
campaigns.

“From the beginning of this study, Orexigen needed a different type of
strategic partner, one who would rethink study startup and enrollment,” said
Michael Narachi, CEO of Orexigen. “Blue Chip Patient Recruitment truly moved
beyond a traditional marketing partner. They customized innovative tactics to
find, understand and engage with the targeted patient. We believe that the
approach we experienced with BCPR will be seen as an industry benchmark for
future patient enrollment projects.”

“Working with a forward-thinking company like Orexigen gave us the opportunity
to innovate and push the traditional boundaries of patient recruitment
marketing and communications,” says Neil Weisman, executive vice president and
general manager of Blue Chip Healthcare Marketing. “Through open communication
and a commitment to collaboration between BCPR, Orexigen, CROs and other
partners, we were able to create an effective, holistic marketing plan,
validated with data and market research that exceeded all forecasted
expectations and accelerated enrollment.”

As soon as The Light Study enrollment is officially completed, BCPR will
continue to support patients through a specific and tailored retention plan
for Orexigen.

Contrave is an investigational medication being evaluated for the treatment of
obesity and has been studied to date in clinical trials enrolling more than
4,500 people. Contrave was developed by Orexigen to help to reduce appetite,
increase metabolism and control cravings and over- eating behaviors. Contrave
has been shown to help people lose weight and keep it off for up to one year
and to improve certain measures of health and well being including losing
inches from their waistlines, improving their cholesterol numbers, and making
significant improvements in their blood sugar levels.

According to some estimates, over 1.5 billion adults world-wide are overweight
or obese. According to the Centers for Disease Control and Prevention (CDC),
35.7% of U.S. adults are obese. CDC estimates that in 2008, medical costs
associated with obesity were $147 billion. Some of the leading causes of death
are obesity related, including certain types of cancer, heart disease, stroke,
and type 2 diabetes.

About Blue Chip Marketing Worldwide

Blue Chip Marketing Worldwide (www.bluechipmarketingworldwide.com), this year
celebrating its 30^th anniversary, is an independent, full-service global
marketing agency that delivers results by uniting brands to sales for clients
in the retail, healthcare and branding sectors. Named to the Crain’s Fast
Fifty and Promo 100 for the past two years, Blue Chip is a leader in shopper
marketing and patient recruitment. The agency has succeeded in helping
high-profile clients such as Procter & Gamble, Gorton’s, Weight Watchers, Blue
Bunny, Fisher, On-Cor, Biosante Pharmaceuticals, Orexigen Therapeutics and
Alva Amco reach their target consumers through the creation and execution of
innovative, multi-platform marketing campaigns. Blue Chip Marketing Worldwide
is based in Northbrook, IL.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the
treatment of obesity. The Company’s lead product candidate is Contrave, which
has completed PhaseIIIclinical trials and for which a New Drug Application
has been submitted and reviewed by theFDA. The Company has also reached
agreement with theFDAon a Special Protocol Assessment (SPA) for the Light
Study, the Contrave cardiovascular outcomes trial. The Company’s other product
candidate, Empatic™, has completed Phase II clinical trials. Further
information about the Company can be found at www.orexigen.com.

Contact:

Blue Chip Marketing Worldwide
Stephanie Sipe, 847-418-2474
ssipe@bluechipww.com
or
Orexigen Therapeutics
McDavid Stilwell, 858-875-8629
mstilwell@orexigen.com
 
Press spacebar to pause and continue. Press esc to stop.